Procter & Gamble Beats EPS by $0.02 with 1.5% Revenue Growth; JPMorgan Lifts Target to $165

PGPG

Procter & Gamble posted $1.88 EPS, beating estimates by $0.02 on $22.21 billion revenue, up 1.5% year-over-year, and reaffirmed FY2026 EPS guidance of $6.83–$7.09. JPMorgan upgraded to overweight with a $165 price target, and GDS Wealth increased its stake by 20.9% to 81,190 shares.

1. Procter & Gamble’s Market Valuation and Growth Prospects

Procter & Gamble shares are trading near decade-low multiples after the market largely discounted the company’s slow but steady organic sales growth. In its most recent quarter, P&G delivered revenue of $22.21 billion, up 1.5% year-over-year, and reported EPS of $1.88, matching the prior year’s result and narrowly beating consensus by $0.02. Management reiterated full-year guidance of $6.83–$7.09 in EPS for fiscal 2026, reflecting a mid-single-digit growth trajectory. With a long history of expanding free cash flow, the current valuation implies a discount to historical averages despite a return on equity of 32.1% and a net margin of 19.3%.

2. Institutional Ownership Trends

In the third quarter, GDS Wealth Management increased its stake in Procter & Gamble by 20.9%, adding 14,060 shares to reach a total of 81,190 shares valued at approximately $12.48 million. Other notable moves include BAM Wealth Management’s new $678,000 position, Acorn Wealth Advisors raising its holdings by 4.5% to 4,028 shares, and PFG Investments’ 1.6% increase to 54,237 shares. Overall, institutional investors and hedge funds collectively own 65.8% of the company’s outstanding stock, underscoring continued confidence from large fiduciaries.

3. Analyst Ratings and Price Targets

Over the past quarter, fourteen research firms have maintained Buy ratings on P&G, while eight have assigned Hold. JPMorgan Chase upgraded its rating from Neutral to Overweight and raised its target to $165; UBS boosted its Buy target to $170; Piper Sandler initiated coverage with a Neutral rating and $150 target; Wells Fargo lifted its objective to $165 with an Overweight view; and Raymond James lowered its target from $185 to $175 but kept an Outperform stance. The consensus moderate-buy recommendation corresponds to an average price target of about $166.70, reflecting upside potential of roughly 10% from current levels.

4. Dividend Policy and Balance Sheet Strength

Procter & Gamble continues to reward shareholders with a quarterly dividend of $1.0568 per share, representing an annualized payout of $4.23 and a yield near 2.8%. The company’s payout ratio stands at 62.7%, supported by robust free cash flow generation. With a debt-to-equity ratio of 0.48, a current ratio of 0.72 and a quick ratio of 0.51, P&G maintains a conservative balance sheet that underpins both ongoing dividend increases and opportunistic share repurchases.

Sources

MGDDD
+1 more